Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
TNF inhibitors are a class of biologic medications used in the treatment of plaque psoriasis,a common form of the disease characterized by raised,red patches covered with a silvery white buildup of dead skin cells.By blocking TNF-alpha,these drugs help reduce inflammation and slow down the excessive growth of skin cells that cause plaques.
The global TNF Inhibitors for the Treatment of Plaque Psoriasis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Forecast” looks at past sales and reviews total world TNF Inhibitors for the Treatment of Plaque Psoriasis sales in 2023, providing a comprehensive analysis by region and market sector of projected TNF Inhibitors for the Treatment of Plaque Psoriasis sales for 2024 through 2030. With TNF Inhibitors for the Treatment of Plaque Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TNF Inhibitors for the Treatment of Plaque Psoriasis industry.
This Insight Report provides a comprehensive analysis of the global TNF Inhibitors for the Treatment of Plaque Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TNF Inhibitors for the Treatment of Plaque Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TNF Inhibitors for the Treatment of Plaque Psoriasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TNF Inhibitors for the Treatment of Plaque Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TNF Inhibitors for the Treatment of Plaque Psoriasis.
United States market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key TNF Inhibitors for the Treatment of Plaque Psoriasis players cover Amgen, AbbVie, Janssen Biotech, Pfizer, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of TNF Inhibitors for the Treatment of Plaque Psoriasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global TNF Inhibitors for the Treatment of Plaque Psoriasis market?
What factors are driving TNF Inhibitors for the Treatment of Plaque Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do TNF Inhibitors for the Treatment of Plaque Psoriasis market opportunities vary by end market size?
How does TNF Inhibitors for the Treatment of Plaque Psoriasis break out by Type, by Application?
TNF inhibitors are a class of biologic medications used in the treatment of plaque psoriasis,a common form of the disease characterized by raised,red patches covered with a silvery white buildup of dead skin cells.By blocking TNF-alpha,these drugs help reduce inflammation and slow down the excessive growth of skin cells that cause plaques.
The global TNF Inhibitors for the Treatment of Plaque Psoriasis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Forecast” looks at past sales and reviews total world TNF Inhibitors for the Treatment of Plaque Psoriasis sales in 2023, providing a comprehensive analysis by region and market sector of projected TNF Inhibitors for the Treatment of Plaque Psoriasis sales for 2024 through 2030. With TNF Inhibitors for the Treatment of Plaque Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TNF Inhibitors for the Treatment of Plaque Psoriasis industry.
This Insight Report provides a comprehensive analysis of the global TNF Inhibitors for the Treatment of Plaque Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TNF Inhibitors for the Treatment of Plaque Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TNF Inhibitors for the Treatment of Plaque Psoriasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TNF Inhibitors for the Treatment of Plaque Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TNF Inhibitors for the Treatment of Plaque Psoriasis.
United States market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key TNF Inhibitors for the Treatment of Plaque Psoriasis players cover Amgen, AbbVie, Janssen Biotech, Pfizer, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of TNF Inhibitors for the Treatment of Plaque Psoriasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Etanercept
- Infliximab
- Adalimumab
- Certolizumab pegol
- Other
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- AbbVie
- Janssen Biotech
- Pfizer
- Samsung Bioepis
- UCB
- Sandoz
- Boehringer Ingelheim Pharmaceuticals
- Biocon Biologics
- Coherus BioSciences
- YL Biologics
- Celltrion
- Teva
- Innovent Biologics
- Bio-Thera Solutions
- Sino Cell Technologies
- Hangzhou Bozhirui Biopharmaceuticals
- Chia Tai Tianqing Pharmaceutical
- Hisun Pharmaceuticals
What is the 10-year outlook for the global TNF Inhibitors for the Treatment of Plaque Psoriasis market?
What factors are driving TNF Inhibitors for the Treatment of Plaque Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do TNF Inhibitors for the Treatment of Plaque Psoriasis market opportunities vary by end market size?
How does TNF Inhibitors for the Treatment of Plaque Psoriasis break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Country/Region, 2019, 2023 & 2030
2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type
2.2.1 Etanercept
2.2.2 Infliximab
2.2.3 Adalimumab
2.2.4 Certolizumab pegol
2.2.5 Other
2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type
2.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2019-2024)
2.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Type (2019-2024)
2.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Type (2019-2024)
2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application
2.5.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)
2.5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Application (2019-2024)
2.5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Breakdown Data by Company
3.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Company (2019-2024)
3.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)
3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Company (2019-2024)
3.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (2019-2024)
3.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)
3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Company
3.4 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Product Location Distribution
3.4.2 Players TNF Inhibitors for the Treatment of Plaque Psoriasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION
4.1 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Geographic Region (2019-2024)
4.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Geographic Region (2019-2024)
4.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country/Region (2019-2024)
4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Country/Region (2019-2024)
4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Country/Region (2019-2024)
4.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.4 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.5 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.6 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
5 AMERICAS
5.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country
5.1.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
5.1.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
5.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
5.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region
6.1.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2019-2024)
6.1.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2019-2024)
6.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
6.3 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis by Country
7.1.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
7.1.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
7.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
7.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis by Country
8.1.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
8.1.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
8.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
8.3 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis
10.3 Manufacturing Process Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis
10.4 Industry Chain Structure of TNF Inhibitors for the Treatment of Plaque Psoriasis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
11.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customer
12 WORLD FORECAST REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION
12.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Forecast by Region
12.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Region (2025-2030)
12.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Type (2025-2030)
12.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.1.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AbbVie
13.2.1 AbbVie Company Information
13.2.2 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.2.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AbbVie Main Business Overview
13.2.5 AbbVie Latest Developments
13.3 Janssen Biotech
13.3.1 Janssen Biotech Company Information
13.3.2 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.3.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Janssen Biotech Main Business Overview
13.3.5 Janssen Biotech Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.4.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.5.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 UCB
13.6.1 UCB Company Information
13.6.2 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.6.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 UCB Main Business Overview
13.6.5 UCB Latest Developments
13.7 Sandoz
13.7.1 Sandoz Company Information
13.7.2 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.7.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sandoz Main Business Overview
13.7.5 Sandoz Latest Developments
13.8 Boehringer Ingelheim Pharmaceuticals
13.8.1 Boehringer Ingelheim Pharmaceuticals Company Information
13.8.2 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.8.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Boehringer Ingelheim Pharmaceuticals Main Business Overview
13.8.5 Boehringer Ingelheim Pharmaceuticals Latest Developments
13.9 Biocon Biologics
13.9.1 Biocon Biologics Company Information
13.9.2 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.9.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Biocon Biologics Main Business Overview
13.9.5 Biocon Biologics Latest Developments
13.10 Coherus BioSciences
13.10.1 Coherus BioSciences Company Information
13.10.2 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.10.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Coherus BioSciences Main Business Overview
13.10.5 Coherus BioSciences Latest Developments
13.11 YL Biologics
13.11.1 YL Biologics Company Information
13.11.2 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.11.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 YL Biologics Main Business Overview
13.11.5 YL Biologics Latest Developments
13.12 Celltrion
13.12.1 Celltrion Company Information
13.12.2 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.12.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Celltrion Main Business Overview
13.12.5 Celltrion Latest Developments
13.13 Teva
13.13.1 Teva Company Information
13.13.2 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.13.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Teva Main Business Overview
13.13.5 Teva Latest Developments
13.14 Innovent Biologics
13.14.1 Innovent Biologics Company Information
13.14.2 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.14.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Innovent Biologics Main Business Overview
13.14.5 Innovent Biologics Latest Developments
13.15 Bio-Thera Solutions
13.15.1 Bio-Thera Solutions Company Information
13.15.2 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.15.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Bio-Thera Solutions Main Business Overview
13.15.5 Bio-Thera Solutions Latest Developments
13.16 Sino Cell Technologies
13.16.1 Sino Cell Technologies Company Information
13.16.2 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.16.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Sino Cell Technologies Main Business Overview
13.16.5 Sino Cell Technologies Latest Developments
13.17 Hangzhou Bozhirui Biopharmaceuticals
13.17.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
13.17.2 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.17.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Hangzhou Bozhirui Biopharmaceuticals Main Business Overview
13.17.5 Hangzhou Bozhirui Biopharmaceuticals Latest Developments
13.18 Chia Tai Tianqing Pharmaceutical
13.18.1 Chia Tai Tianqing Pharmaceutical Company Information
13.18.2 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.18.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.18.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.19 Hisun Pharmaceuticals
13.19.1 Hisun Pharmaceuticals Company Information
13.19.2 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.19.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Hisun Pharmaceuticals Main Business Overview
13.19.5 Hisun Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1.TNF Inhibitors for theTreatment of Plaque Psoriasis Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2.TNF Inhibitors for theTreatment of Plaque Psoriasis Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Etanercept
Table 4. Major Players of Infliximab
Table 5. Major Players of Adalimumab
Table 6. Major Players of Certolizumab pegol
Table 7. Major Players of Other
Table 8. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 9. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Table 10. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue byType (2019-2024) & ($ million)
Table 11. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share byType (2019-2024)
Table 12. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price byType (2019-2024) & (US$/Unit)
Table 13. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale by Application (2019-2024) & (K Units)
Table 14. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)
Table 15. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Application (2019-2024) & ($ million)
Table 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application (2019-2024)
Table 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company (2019-2024) & (K Units)
Table 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)
Table 20. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Company (2019-2024) & ($ millions)
Table 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)
Table 22. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key ManufacturersTNF Inhibitors for theTreatment of Plaque Psoriasis Producing Area Distribution and Sales Area
Table 24. PlayersTNF Inhibitors for theTreatment of Plaque Psoriasis Products Offered
Table 25.TNF Inhibitors for theTreatment of Plaque Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019-2024) & (K Units)
Table 29. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share Geographic Region (2019-2024)
Table 30. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Geographic Region (2019-2024)
Table 32. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country/Region (2019-2024) & (K Units)
Table 33. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019-2024)
Table 34. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country/Region (2019-2024)
Table 36. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 37. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country (2019-2024)
Table 38. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & ($ millions)
Table 39. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 40. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 41. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Region (2019-2024) & (K Units)
Table 42. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region (2019-2024)
Table 43. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Region (2019-2024) & ($ millions)
Table 44. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 45. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 46. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 47. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & ($ millions)
Table 48. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 49. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 50. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 51. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Table 52. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 53. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 55. Key Market Challenges & Risks ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 56. Key IndustryTrends ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 57.TNF Inhibitors for theTreatment of Plaque Psoriasis Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59.TNF Inhibitors for theTreatment of Plaque Psoriasis Distributors List
Table 60.TNF Inhibitors for theTreatment of Plaque Psoriasis Customer List
Table 61. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Region (2025-2030) & (K Units)
Table 62. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Region (2025-2030) & ($ millions)
Table 63. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 64. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 65. APACTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Region (2025-2030) & (K Units)
Table 66. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 67. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 68. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 70. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast byType (2025-2030) & (K Units)
Table 72. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast byType (2025-2030) & ($ millions)
Table 73. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Application (2025-2030) & (K Units)
Table 74. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Application (2025-2030) & ($ millions)
Table 75. Amgen Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 76. AmgenTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 77. AmgenTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Main Business
Table 79. Amgen Latest Developments
Table 80. AbbVie Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 81. AbbVieTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 82. AbbVieTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. AbbVie Main Business
Table 84. AbbVie Latest Developments
Table 85. Janssen Biotech Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 86. Janssen BiotechTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 87. Janssen BiotechTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Janssen Biotech Main Business
Table 89. Janssen Biotech Latest Developments
Table 90. Pfizer Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 91. PfizerTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 92. PfizerTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Samsung Bioepis Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 96. Samsung BioepisTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 97. Samsung BioepisTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Samsung Bioepis Main Business
Table 99. Samsung Bioepis Latest Developments
Table 100. UCB Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 101. UCBTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 102. UCBTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. UCB Main Business
Table 104. UCB Latest Developments
Table 105. Sandoz Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 106. SandozTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 107. SandozTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Sandoz Main Business
Table 109. Sandoz Latest Developments
Table 110. Boehringer Ingelheim Pharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 111. Boehringer Ingelheim PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 112. Boehringer Ingelheim PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Boehringer Ingelheim Pharmaceuticals Main Business
Table 114. Boehringer Ingelheim Pharmaceuticals Latest Developments
Table 115. Biocon Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 116. Biocon BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 117. Biocon BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Biocon Biologics Main Business
Table 119. Biocon Biologics Latest Developments
Table 120. Coherus BioSciences Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 121. Coherus BioSciencesTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 122. Coherus BioSciencesTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Coherus BioSciences Main Business
Table 124. Coherus BioSciences Latest Developments
Table 125. YL Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 126. YL BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 127. YL BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. YL Biologics Main Business
Table 129. YL Biologics Latest Developments
Table 130. Celltrion Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 131. CelltrionTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 132. CelltrionTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Celltrion Main Business
Table 134. Celltrion Latest Developments
Table 135.Teva Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 136.TevaTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 137.TevaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138.Teva Main Business
Table 139.Teva Latest Developments
Table 140. Innovent Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 141. Innovent BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 142. Innovent BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Innovent Biologics Main Business
Table 144. Innovent Biologics Latest Developments
Table 145. Bio-Thera Solutions Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 146. Bio-Thera SolutionsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 147. Bio-Thera SolutionsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Bio-Thera Solutions Main Business
Table 149. Bio-Thera Solutions Latest Developments
Table 150. Sino CellTechnologies Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 151. Sino CellTechnologiesTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 152. Sino CellTechnologiesTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Sino CellTechnologies Main Business
Table 154. Sino CellTechnologies Latest Developments
Table 155. Hangzhou Bozhirui Biopharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 156. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 157. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Hangzhou Bozhirui Biopharmaceuticals Main Business
Table 159. Hangzhou Bozhirui Biopharmaceuticals Latest Developments
Table 160. ChiaTaiTianqing Pharmaceutical Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 161. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 162. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. ChiaTaiTianqing Pharmaceutical Main Business
Table 164. ChiaTaiTianqing Pharmaceutical Latest Developments
Table 165. Hisun Pharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 166. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 167. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Hisun Pharmaceuticals Main Business
Table 169. Hisun Pharmaceuticals Latest Developments
LIST OFFIGURES
Figure 1. Picture ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 2.TNF Inhibitors for theTreatment of Plaque Psoriasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Growth Rate 2019-2030 (K Units)
Figure 7. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth Rate 2019-2030 ($ millions)
Figure 8.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2023)
Figure 10.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Etanercept
Figure 12. Product Picture of Infliximab
Figure 13. Product Picture of Adalimumab
Figure 14. Product Picture of Certolizumab pegol
Figure 15. Product Picture of Other
Figure 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType in 2023
Figure 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share byType (2019-2024)
Figure 18.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Hospital and Clinic
Figure 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 20.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Retail Pharmacies
Figure 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 22.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Other
Figure 23. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Other (2019-2024) & (K Units)
Figure 24. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Market Share by Application (2023)
Figure 25. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application in 2023
Figure 26.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company in 2023 (K Units)
Figure 27. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Company in 2023
Figure 28.TNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Company in 2023 ($ millions)
Figure 29. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Company in 2023
Figure 30. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Geographic Region (2019-2024)
Figure 31. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Geographic Region in 2023
Figure 32. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 33. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 34. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 35. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 36. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 37. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 38. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 39. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 40. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country in 2023
Figure 41. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Figure 42. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 43. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 44. United StatesTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 45. CanadaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 46. MexicoTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 47. BrazilTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 48. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region in 2023
Figure 49. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Region (2019-2024)
Figure 50. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 51. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 52. ChinaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 53. JapanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 54. South KoreaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 55. Southeast AsiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 56. IndiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 57. AustraliaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 58. ChinaTaiwanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 59. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country in 2023
Figure 60. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Figure 61. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 62. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 63. GermanyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 64.FranceTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 65. UKTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 66. ItalyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 67. RussiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 68. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country (2019-2024)
Figure 69. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 70. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 71. EgyptTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 72. South AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 73. IsraelTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 74.TurkeyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 75. GCC CountriesTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis ofTNF Inhibitors for theTreatment of Plaque Psoriasis in 2023
Figure 77. Manufacturing Process Analysis ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 78. Industry Chain Structure ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 79. Channels of Distribution
Figure 80. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales MarketForecast by Region (2025-2030)
Figure 81. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast by Region (2025-2030)
Figure 82. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market ShareForecast byType (2025-2030)
Figure 83. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast byType (2025-2030)
Figure 84. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market ShareForecast by Application (2025-2030)
Figure 85. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Country/Region, 2019, 2023 & 2030
2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type
2.2.1 Etanercept
2.2.2 Infliximab
2.2.3 Adalimumab
2.2.4 Certolizumab pegol
2.2.5 Other
2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type
2.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2019-2024)
2.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Type (2019-2024)
2.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Type (2019-2024)
2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application
2.5.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)
2.5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Application (2019-2024)
2.5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Breakdown Data by Company
3.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Company (2019-2024)
3.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)
3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Company (2019-2024)
3.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (2019-2024)
3.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)
3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Company
3.4 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Product Location Distribution
3.4.2 Players TNF Inhibitors for the Treatment of Plaque Psoriasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION
4.1 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Geographic Region (2019-2024)
4.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Geographic Region (2019-2024)
4.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country/Region (2019-2024)
4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Country/Region (2019-2024)
4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Country/Region (2019-2024)
4.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.4 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.5 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
4.6 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth
5 AMERICAS
5.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country
5.1.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
5.1.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
5.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
5.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region
6.1.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2019-2024)
6.1.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2019-2024)
6.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
6.3 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis by Country
7.1.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
7.1.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
7.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
7.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis by Country
8.1.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)
8.1.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)
8.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)
8.3 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis
10.3 Manufacturing Process Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis
10.4 Industry Chain Structure of TNF Inhibitors for the Treatment of Plaque Psoriasis
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
11.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customer
12 WORLD FORECAST REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION
12.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Forecast by Region
12.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Region (2025-2030)
12.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Type (2025-2030)
12.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.1.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AbbVie
13.2.1 AbbVie Company Information
13.2.2 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.2.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AbbVie Main Business Overview
13.2.5 AbbVie Latest Developments
13.3 Janssen Biotech
13.3.1 Janssen Biotech Company Information
13.3.2 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.3.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Janssen Biotech Main Business Overview
13.3.5 Janssen Biotech Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.4.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.5.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 UCB
13.6.1 UCB Company Information
13.6.2 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.6.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 UCB Main Business Overview
13.6.5 UCB Latest Developments
13.7 Sandoz
13.7.1 Sandoz Company Information
13.7.2 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.7.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sandoz Main Business Overview
13.7.5 Sandoz Latest Developments
13.8 Boehringer Ingelheim Pharmaceuticals
13.8.1 Boehringer Ingelheim Pharmaceuticals Company Information
13.8.2 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.8.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Boehringer Ingelheim Pharmaceuticals Main Business Overview
13.8.5 Boehringer Ingelheim Pharmaceuticals Latest Developments
13.9 Biocon Biologics
13.9.1 Biocon Biologics Company Information
13.9.2 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.9.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Biocon Biologics Main Business Overview
13.9.5 Biocon Biologics Latest Developments
13.10 Coherus BioSciences
13.10.1 Coherus BioSciences Company Information
13.10.2 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.10.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Coherus BioSciences Main Business Overview
13.10.5 Coherus BioSciences Latest Developments
13.11 YL Biologics
13.11.1 YL Biologics Company Information
13.11.2 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.11.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 YL Biologics Main Business Overview
13.11.5 YL Biologics Latest Developments
13.12 Celltrion
13.12.1 Celltrion Company Information
13.12.2 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.12.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Celltrion Main Business Overview
13.12.5 Celltrion Latest Developments
13.13 Teva
13.13.1 Teva Company Information
13.13.2 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.13.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Teva Main Business Overview
13.13.5 Teva Latest Developments
13.14 Innovent Biologics
13.14.1 Innovent Biologics Company Information
13.14.2 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.14.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Innovent Biologics Main Business Overview
13.14.5 Innovent Biologics Latest Developments
13.15 Bio-Thera Solutions
13.15.1 Bio-Thera Solutions Company Information
13.15.2 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.15.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Bio-Thera Solutions Main Business Overview
13.15.5 Bio-Thera Solutions Latest Developments
13.16 Sino Cell Technologies
13.16.1 Sino Cell Technologies Company Information
13.16.2 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.16.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Sino Cell Technologies Main Business Overview
13.16.5 Sino Cell Technologies Latest Developments
13.17 Hangzhou Bozhirui Biopharmaceuticals
13.17.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
13.17.2 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.17.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Hangzhou Bozhirui Biopharmaceuticals Main Business Overview
13.17.5 Hangzhou Bozhirui Biopharmaceuticals Latest Developments
13.18 Chia Tai Tianqing Pharmaceutical
13.18.1 Chia Tai Tianqing Pharmaceutical Company Information
13.18.2 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.18.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.18.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.19 Hisun Pharmaceuticals
13.19.1 Hisun Pharmaceuticals Company Information
13.19.2 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
13.19.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Hisun Pharmaceuticals Main Business Overview
13.19.5 Hisun Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1.TNF Inhibitors for theTreatment of Plaque Psoriasis Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2.TNF Inhibitors for theTreatment of Plaque Psoriasis Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Etanercept
Table 4. Major Players of Infliximab
Table 5. Major Players of Adalimumab
Table 6. Major Players of Certolizumab pegol
Table 7. Major Players of Other
Table 8. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 9. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Table 10. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue byType (2019-2024) & ($ million)
Table 11. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share byType (2019-2024)
Table 12. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price byType (2019-2024) & (US$/Unit)
Table 13. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale by Application (2019-2024) & (K Units)
Table 14. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)
Table 15. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Application (2019-2024) & ($ million)
Table 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application (2019-2024)
Table 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company (2019-2024) & (K Units)
Table 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)
Table 20. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Company (2019-2024) & ($ millions)
Table 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)
Table 22. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key ManufacturersTNF Inhibitors for theTreatment of Plaque Psoriasis Producing Area Distribution and Sales Area
Table 24. PlayersTNF Inhibitors for theTreatment of Plaque Psoriasis Products Offered
Table 25.TNF Inhibitors for theTreatment of Plaque Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019-2024) & (K Units)
Table 29. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share Geographic Region (2019-2024)
Table 30. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Geographic Region (2019-2024)
Table 32. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country/Region (2019-2024) & (K Units)
Table 33. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019-2024)
Table 34. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country/Region (2019-2024)
Table 36. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 37. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country (2019-2024)
Table 38. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & ($ millions)
Table 39. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 40. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 41. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Region (2019-2024) & (K Units)
Table 42. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region (2019-2024)
Table 43. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Region (2019-2024) & ($ millions)
Table 44. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 45. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 46. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 47. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & ($ millions)
Table 48. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 49. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 50. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)
Table 51. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Table 52. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)
Table 53. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 55. Key Market Challenges & Risks ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 56. Key IndustryTrends ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Table 57.TNF Inhibitors for theTreatment of Plaque Psoriasis Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59.TNF Inhibitors for theTreatment of Plaque Psoriasis Distributors List
Table 60.TNF Inhibitors for theTreatment of Plaque Psoriasis Customer List
Table 61. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Region (2025-2030) & (K Units)
Table 62. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Region (2025-2030) & ($ millions)
Table 63. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 64. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 65. APACTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Region (2025-2030) & (K Units)
Table 66. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 67. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 68. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Country (2025-2030) & (K Units)
Table 70. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Country (2025-2030) & ($ millions)
Table 71. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast byType (2025-2030) & (K Units)
Table 72. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast byType (2025-2030) & ($ millions)
Table 73. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis SalesForecast by Application (2025-2030) & (K Units)
Table 74. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis RevenueForecast by Application (2025-2030) & ($ millions)
Table 75. Amgen Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 76. AmgenTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 77. AmgenTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Main Business
Table 79. Amgen Latest Developments
Table 80. AbbVie Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 81. AbbVieTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 82. AbbVieTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. AbbVie Main Business
Table 84. AbbVie Latest Developments
Table 85. Janssen Biotech Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 86. Janssen BiotechTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 87. Janssen BiotechTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Janssen Biotech Main Business
Table 89. Janssen Biotech Latest Developments
Table 90. Pfizer Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 91. PfizerTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 92. PfizerTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Main Business
Table 94. Pfizer Latest Developments
Table 95. Samsung Bioepis Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 96. Samsung BioepisTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 97. Samsung BioepisTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Samsung Bioepis Main Business
Table 99. Samsung Bioepis Latest Developments
Table 100. UCB Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 101. UCBTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 102. UCBTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. UCB Main Business
Table 104. UCB Latest Developments
Table 105. Sandoz Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 106. SandozTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 107. SandozTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Sandoz Main Business
Table 109. Sandoz Latest Developments
Table 110. Boehringer Ingelheim Pharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 111. Boehringer Ingelheim PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 112. Boehringer Ingelheim PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Boehringer Ingelheim Pharmaceuticals Main Business
Table 114. Boehringer Ingelheim Pharmaceuticals Latest Developments
Table 115. Biocon Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 116. Biocon BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 117. Biocon BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Biocon Biologics Main Business
Table 119. Biocon Biologics Latest Developments
Table 120. Coherus BioSciences Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 121. Coherus BioSciencesTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 122. Coherus BioSciencesTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Coherus BioSciences Main Business
Table 124. Coherus BioSciences Latest Developments
Table 125. YL Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 126. YL BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 127. YL BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. YL Biologics Main Business
Table 129. YL Biologics Latest Developments
Table 130. Celltrion Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 131. CelltrionTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 132. CelltrionTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Celltrion Main Business
Table 134. Celltrion Latest Developments
Table 135.Teva Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 136.TevaTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 137.TevaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138.Teva Main Business
Table 139.Teva Latest Developments
Table 140. Innovent Biologics Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 141. Innovent BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 142. Innovent BiologicsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Innovent Biologics Main Business
Table 144. Innovent Biologics Latest Developments
Table 145. Bio-Thera Solutions Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 146. Bio-Thera SolutionsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 147. Bio-Thera SolutionsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Bio-Thera Solutions Main Business
Table 149. Bio-Thera Solutions Latest Developments
Table 150. Sino CellTechnologies Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 151. Sino CellTechnologiesTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 152. Sino CellTechnologiesTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Sino CellTechnologies Main Business
Table 154. Sino CellTechnologies Latest Developments
Table 155. Hangzhou Bozhirui Biopharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 156. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 157. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Hangzhou Bozhirui Biopharmaceuticals Main Business
Table 159. Hangzhou Bozhirui Biopharmaceuticals Latest Developments
Table 160. ChiaTaiTianqing Pharmaceutical Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 161. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 162. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. ChiaTaiTianqing Pharmaceutical Main Business
Table 164. ChiaTaiTianqing Pharmaceutical Latest Developments
Table 165. Hisun Pharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 166. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications
Table 167. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Hisun Pharmaceuticals Main Business
Table 169. Hisun Pharmaceuticals Latest Developments
LIST OFFIGURES
Figure 1. Picture ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 2.TNF Inhibitors for theTreatment of Plaque Psoriasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Growth Rate 2019-2030 (K Units)
Figure 7. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth Rate 2019-2030 ($ millions)
Figure 8.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2023)
Figure 10.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Etanercept
Figure 12. Product Picture of Infliximab
Figure 13. Product Picture of Adalimumab
Figure 14. Product Picture of Certolizumab pegol
Figure 15. Product Picture of Other
Figure 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType in 2023
Figure 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share byType (2019-2024)
Figure 18.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Hospital and Clinic
Figure 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 20.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Retail Pharmacies
Figure 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 22.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Other
Figure 23. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Other (2019-2024) & (K Units)
Figure 24. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Market Share by Application (2023)
Figure 25. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application in 2023
Figure 26.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company in 2023 (K Units)
Figure 27. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Company in 2023
Figure 28.TNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Company in 2023 ($ millions)
Figure 29. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Company in 2023
Figure 30. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Geographic Region (2019-2024)
Figure 31. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Geographic Region in 2023
Figure 32. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 33. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 34. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 35. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 36. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 37. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 38. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales 2019-2024 (K Units)
Figure 39. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue 2019-2024 ($ millions)
Figure 40. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country in 2023
Figure 41. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Figure 42. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 43. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 44. United StatesTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 45. CanadaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 46. MexicoTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 47. BrazilTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 48. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region in 2023
Figure 49. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Region (2019-2024)
Figure 50. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 51. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 52. ChinaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 53. JapanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 54. South KoreaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 55. Southeast AsiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 56. IndiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 57. AustraliaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 58. ChinaTaiwanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 59. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country in 2023
Figure 60. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)
Figure 61. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 62. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 63. GermanyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 64.FranceTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 65. UKTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 66. ItalyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 67. RussiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 68. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country (2019-2024)
Figure 69. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)
Figure 70. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)
Figure 71. EgyptTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 72. South AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 73. IsraelTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 74.TurkeyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 75. GCC CountriesTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis ofTNF Inhibitors for theTreatment of Plaque Psoriasis in 2023
Figure 77. Manufacturing Process Analysis ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 78. Industry Chain Structure ofTNF Inhibitors for theTreatment of Plaque Psoriasis
Figure 79. Channels of Distribution
Figure 80. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales MarketForecast by Region (2025-2030)
Figure 81. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast by Region (2025-2030)
Figure 82. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market ShareForecast byType (2025-2030)
Figure 83. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast byType (2025-2030)
Figure 84. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market ShareForecast by Application (2025-2030)
Figure 85. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market ShareForecast by Application (2025-2030)
